New rifamycins for the treatment of bacterial infections

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 5, 2007, Pages 475-485

  Combrink, Keith D ^a   Lynch, A Simon ^a  

^a Cumbre Pharmaceuticals Inc   (United States)

Author keywords

Biofilm; Device related infection; Hybrid antibiotic; Mycobacterium tuberculosis; Rifalazil; Rifampin; Rifamycin; Rifapentine; Rifaximin; Ritabutin; RNA polymerase; RpoB

Indexed keywords

AMOXICILLIN; ANILINOURACIL; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BENZOXAZINORIFAMYCIN DERIVATIVE; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CYTOCHROME P450; CYTOCHROME P450 3A; MACROLIDE; METICILLIN; OXAZOLIDINONE DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFABUTIN DERIVATIVE; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RIFAXIMIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTERY DISEASE; BACTERIAL INFECTION; BACTERIAL MUTATION; BIOFILM; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COMBINATION CHEMOTHERAPY; DEVICE INFECTION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRY POWDER; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE INFECTION; ISCHEMIC HEART DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PATENT; PHARMACODYNAMICS; PHARMACOPHORE; REVIEW; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; TRAVELLER DIARRHEA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 34248362366     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.5.475     Document Type: Review

References (50)

1. FLOSS HG, YU T-W: Rifamycin: mode of action, resistance and biosynthesis. Chem. Rev, (2005) 105:621-632.
2. MORRIS AB, BROWN RB, SANDS M: Use of rifampin in non-staphylococcal, non-mycobacterial disease. Antimicrob. Agents Chemother. (1993): 37:1-7.
3. CHAISSON RE: Treatment of chronic infections with rifamycins: is resistance likely to follow? Antimicrob. Agents Chemother. (2003) 47:3037-3039.
4. CAMPBELL EA, KORZHEVA N, MUSTAEV A: Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. (2001) 104:901-912.
5. ARTSIMOVITXH I, VASSYLYEVA MN, SVETLOV D et al.: Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell (2005) 122:351-363.
6. COMBRINK, KD, DENTON DA, HARRAN S et al.: New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Bioorg. Med. Chem. Lett. (2007) 17:522-526.
7. DRLICA K, ZHAO X: Mutant selection window hypothesis updated. Clin. Infect. Dis. (2007) 44(5):681-688.
8. ZHAO X, DRLICA K: Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. (2002) 185:561-565.
9. HOBBY L, LENERT TF: The action of rifampin alone and in combination with other antituberculosis drugs. Am. Rev. Respir. Dis. (1970) 102:462-465.
10. RAAD I, DAROUICHE R, HACHEM R et al.: Antibiotics and prevention of Microbiol colonization of catheters. Antimicrob. Agents Chemother. (1995) 39(11):2397-2400,
11. SCHWANK S, RAJACIC Z, ZIMMERLI W et al.: Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob. Agents Chemother (1998) 42(4):895-898.
12. SVENSSON E, HANBERGER H, NILSSON M et al.: Factors affecting the development of rifampicin resistance in biofilm-producing Staphylococcus epidermidis. J. Antimicrob. Chemother. (1997) 39:817-820.
13. JONES SM, MORGAN M, HUMPHREY TJ et al.: Effect of vancomycin and rifampicin on methicillin-resistant Staphylococcus aureus biofilms. Lancet (2001) 357:40-41.
14. DRANCOUR'F M, STEIN A, ARGENOSN JN et al.: Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. (1997) 39:235-240.
15. ZIMMERLI W, WIDMER AF. BLATTER M et al.: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA (1998) 279:1537-1541.
16. WIDMER AF, GAECHTER A, OCHSNER PE et al.: Antimicrobiol treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. (1992) 14(6):1251-1253.
17. ZIMMERLI W, WIDMER AF, BLATTER M et al.: Role of rifampin for treatment of orthopedic implant-related sraphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA (1998) 279(19):1537-1541.
18. SCHRENZEL J, HARBARTH S, SCHOCKMEL G et al.: A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vanconrycin for the treatment of staphylococcal infection, Clin. Infect. Dis. (2004) 39(9):1285-1292.
19. ZIMMERLI W, TRAMPUZ A, OCHSNER PE: Prosthetic-joint infectious. New Engl. J. Med. (2004) 351(16):1645-1654.
20. PERRI F, FESTA V, CLEMENTE R et al.: Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Alimen. Pharmacol. Ther. (2000) 14:311-316.
21. BURMAN WJ, GALLICANO K, PELOQUIN C: Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Phamacokinetic (2001) 40(5):327-341.
22. REINACH B, DE SOUSA G, DOSTERT P et al.: Comparative effect of rifabutin and rifampicin on cyctochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chemico-Biological Interactions (1999) 121:37-48.
23. MAE T, HOSOE, K, YAMAMOTOT T et al.: Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica (1998) 28(8):759-766.
24. ROTHSTEIN DM, SHALIS C, MURPHY CK et al.: Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin. Investig. Drugs (2006) 15(6):603-623.
25. ACOCELLA G: Pharmacokinetics and metabolism of rifampin in humans. Rev. Infectious Dis. (1983) 5:S428-S432.
26. JAMIS-DOW CA, KATKI AG, COLLINS JM et al.: Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica (1997) 27:1015-1024.
27. MAE T, INABA T, KONISHI E et al.: Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica (2000) 30:565-574.
28. BARTOLUCCI C, CELLAI C, SILVIO C et al.: Synthesis, reactivity studies, and x-ray crystal structure of (11R)-25-O-deacetyl-11-deoxo-11-hydroxy-21,23-O- isopropylidener ifamycin S. Helvetica. Chimica. Acta. (1990) 73(1):185-98.
29. MAGGI N, GALLO GG, PASQUALUCCI CR: Rifamycins. LIX. Acetyl migration in rifampicin. J. Med. Chem. (1968): 11:936-939.
30. MAHDI OS, KALAYOGLU M, BYRNE GI: Emerging strategies in the diagnosis, prevention and treatment of chlamydial infections. Expert Opin. Ther. Patents (2001) 11(8):1523-1265.
31. ROTHSTEIN DM, HARTMAN AD, CYNAMON MH et al.: Development potential of rifalazil. Expert Opin. Investig. Drugs (2003) 12(2):255-271.
32. MULLIN S, ROTHSTEIN DM, MURPHY CK: Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes. Antimicrob. Agents Chemother. (2006) 50(5):1908-1909.
33. WICHELHAUS TA, SCHAFER V, BRADE V et al.: Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J. Antimicrob. Chemother. (2001) 47:153-156.
34. YANG B, KOGA H, OHNO H et al.: Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. (1998) 42:621-628.
35. DHOPLE AM, DHOPLE AA, IBANEZ MA: Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents (1997) 8:209-214.
36. LOUNIS N, ROSCIGNO G: In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections. Curr. Pharma. Des. (2004) 10:3229-3238.
37. BARLUENGA J, AZNAR E GARCIA AB et al.: New rifabutin analogs: synthesis and biological activity, against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. (2006) 16:5717-5722.
38. KIM IH, COMBRINK KD, MA Z et al.: Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins. Bioorgan. Med. Chem. Lett (2007) 17:1181-1184.
39. DI STEFANO M, MALSERVISI S, VENETO G et al.: Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. (2000) 14:551-556.
40. BRYSKEIR A: Dual β-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment. Expert Opin. Invest. Drugs (1997) 6(10): 1479-1499.
41. GORDEEV MF, HACKBARTH C, BARBACHYN MR et al.: Novel oxazolidinone-quinolone hybrid antimicrobiols. Bioorgan. Med. Chem. Lett. (2003) 13:4213-4216.
42. HUBSCHWERLEN C, SPECKLIN JL, BAESCHLIN DK et al.: Structure-activity relationship in the oxazolidinone-quinolone hybrid series: Influence of the central spacer on the antibacterial activity and the mode of action. Bioorgan. Med. Chem. Lett. (2003) 13:4229-4233.
43. ZHI C, LONG ZY, MANIKOWSKI A et al.: Hybrid antibacterials: DNA polymerase-topoisomerase inhibitors. J. Med. Chem. (2006) 49(4):1455-1465.
44. BUTLER MM, LAMARR WA, FOSTER KA et al.: Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob. Agents Chemother. (2007) 51(1):119-127.
45. HALL-STOODLEY L, COSTERTON JW, STOODLEY P: Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. (2004) 2(2):95-108.
46. LEWIS K: Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. (2007) 5(1):48-56.
47. ZHENG Z, STEWART PS: Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimcrob. Agents and Chemother. (2002) 46(3):900-903.
48. VERNON A, BURMAN W, BENATOR D et al.: Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet (1999) 353:1843-1847.
49. LIU Y, GUI J, WANG R et al.: Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J. Antimicrob. Chemother. (2005) 56:1172-1175.
50. SEKIGUCHI J, FUJINO T, ARAAKE M et al.: Emergence of rifampicin resistance in methicillin-resistant Staphylococcus aureus in tuberculosis wards. J. Infect. Chemother. (2006) 12(1):47-50.